Aurobindo Pharma receives USFDA Approval for Aripiprazole Tablets

09 Oct 2015 Evaluate

Aurobindo Pharma has received the final approval from the US Food & Drug Administration (USFDA) to manufacture and market Aripiprazole Tablets, 2mg, 5mg, 10mg, 15mg, 20mg and 30mg (ANDA 203908). The product is ready for launch. The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Abilify Tablets 2mg, 5mg, 10mg, 15mg, 20mg and 30mg of Otsuka Pharmaceutical Company (Otsuka).

Aripiprazole Tablets are atypical antipsychotic indicated in the treatment symptoms of psychotic conditions such as schizophrenia and bipolar disorder (manic depression). The approved product has an estimated market size of $7.3 Billion for the twelve months ending August 2015 according to IMS.

This is the 48th ANDA of the company to be approved out of Unit VII formulation facility in Hyderabad, India for manufacturing Oral Non-Antibiotic products. Aurobindo now has a total of 215 ANDA approvals (187 Final approvals including 10 from Aurolife Pharma LLC and 28 Tentative approvals) from USFDA.

Aurobindo Pharma Share Price

1161.85 -14.80 (-1.26%)
09-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1776.20
Dr. Reddys Lab 1246.25
Cipla 1490.70
Zydus Lifesciences 919.90
Lupin 2052.05
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×